Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Matthews

Showing results (461-470 of 464) with videos related to

Pageof 47
Sort By:
You have reached the last page of results.This site can display upto 464 results.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
Pageof 47

Showing results (461-470 of 464) with videos related to

Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 464 results.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
Pageof 47